Target intelligence / Profile preview

Taste receptor type 2 member 50 (TAS2R50)

Target
TAS2R50
Molecular classification
G protein-coupled receptor, Receptor, Taste receptor, Seven-transmembrane protein
01

Overview

Taste receptor type 2 member 50 (TAS2R50) is a **G protein-coupled receptor** (GPCR) that mediates the perception of **bitterness** in humans[1][2][4]. Encoded by the *TAS2R50* gene located on chromosome 12p13.2, this receptor is expressed predominantly in gustatory cells of the tongue but is also found in select non-gustatory tissues[2][6]. TAS2R50 is characterized by a seven-transmembrane domain structure, interacts with bitter compounds such as andrographolide and amarogentin[2][7], and transduces signals via the gustducin G protein pathway, impacting taste perception and possibly influencing dietary preferences. Genetic variation in TAS2R50 has been linked to risk modulation for certain diseases (e.g., myocardial infarction, Parkinson disease) and to interindividual differences in taste and food intake[2][4][6]. Although key for sensory perception, TAS2R50, unlike some other GPCRs, is not currently a drug target for approved therapeutics but contributes to the broader class of GPCRs, which are major pharmacological targets[6].

Other names
Taste receptor type 2 member 51T2R50T2R51TAS2R51
02

Mechanism of action

Agonists bind and activate the receptor, leading to G protein (gustducin) activation, PLC-β2 activation, and downstream TRPM5 channel gating, resulting in cellular depolarization and neurotransmitter release[2][4][6].

03

Biological functions

Signal transductionBitter taste perceptionChemosensory signaling in the gastrointestinal tractGustducin-mediated signaling
04

Disease associations

Cardiovascular disease (notably: association with myocardial infarction and coronary heart disease risk modulation)Parkinson disease (altered expression in patient brains)Otitis mediaPotential roles in other conditions through modulation of dietary intake and metabolic pathways
05

Safety considerations

No established clinical safety concerns; theoretical challenges include off-target taste modulation and variation in receptor expression among individuals.
06

Interacting drugs

Bitter terpenoids (e.g., andrographolide, amarogentin)

1 more in the full profile.

07

Biomarkers

Variants of the TAS2R50 gene (e.g., rs1376251) have been studied as biomarkers for coronary heart disease risk and dietary behavior modulation[2].

Beyond the preview

Go deeper on Taste receptor type 2 member 50 (TAS2R50).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Taste receptor type 2 member 50 (TAS2R50).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call